Quantcast

Industry news that matters to you.  Learn more

Archives for February 2015

ChEMBL 20 Incorporates the Pistoia Alliance’s HELM Annotation

The European Bioinformatics Institute (EMBL-EBI) has released version 20 of ChEMBL, the database of compound bioactivity data and drug targets. ChEMBL now incorporates the Hierarchical Editing Language for Macromolecules (HELM), the macromolecular representation standard recently released by the Pistoia Alliance.

Caprion Announces Agreement To In-License Xpresys Lung From Indi For Canadian Commercialization

Caprion recently announced an exclusive agreement to in-license Xpresys Lung in Canada from Indi (Integrated Diagnostics®). Xpresys Lung is a breakthrough, molecular diagnostic blood test that assists with the management of indeterminate lung nodules. The clinical laboratory developed test is currently only available in the United States and provides physicians with objective information to identify nodules with a high probability of being benign – potentially reducing unnecessary invasive procedures, which may be risky for the patient and costly to the healthcare system.

Catamaran Introducing Innovative Clinical Outcomes-Based Program for Hepatitis C Treatment

Catamaran Corp. (NASDAQ: CTRX, TSX: CCT), a leading provider of pharmacy benefit management (PBM) services and technology, recently announced that it is introducing a new clinical outcomes-based program for hepatitis C treatment through its specialty pharmacy, BriovaRx®.

Researchers Find That Tumor DNA and Cells in the Blood Can Be Used to Diagnose Prostate Cancer and Drug Resistance in Breast Cancer

Last month, the “Molecular Diagnostics” issue of Clinical Chemistry, the journal of AACC, featured new research on a genetic test for prostate cancer that could replace the unreliable prostate specific antigen (PSA) test, as well as a more accurate test for breast cancer drug resistance. Both tests could help patients receive more targeted treatment for prostate and breast cancer, which in the U.S. are the second leading causes of cancer death in men and women, respectively.